Exo announced that it launched its FDA-cleared cardiac and lung AI applications for the Iris handheld ultrasound device.
The company now has FDA clearance for five different applications on Iris — cardiac, lung, bladder, hip and thyroid. It expects to double that number by 2025.
Related: QT imaging’s breast imaging system proves as effective as mammography
Iris delivers high-performance medical imaging at a fraction of the size and cost of cart-based ultrasound. The system, built on Exo’s advanced silicon technology, fits in the pockets of caregivers. It enables immediate answers at the point of care for physicians, nurses, EMTs and clinicians in emergency, acute care, outpatient and home settings.
Exo unveiled the device for versatile imaging performance in point-of-care ultrasound (POCUS) in September 2023.
The company says the launch of its latest Iris functions simplify the process of obtaining and interpreting images specific to the heart and lungs. This allows caregivers — particularly in rural and under-resourced settings — to accelerate diagnosis and treatment regardless of location.
“It’s time for a reimagined approach to addressing heart failure at scale. That’s why Exo is putting AI-empowered medical imaging in the hands of every caregiver, no matter their specialty,” said Sandeep Akkaraju, co-founder and CEO of Exo. “Exo’s AI is simple to use, reproducible and objective, and will contribute to more accessible and reliable healthcare for all.”
